US Stock Market News | Novavax Pharmaceuticals plunges over 19% as FDA halts its flu vaccine clinical trial

智通財經
2024.10.16 15:50

週三，諾瓦瓦克斯醫藥股價大幅下跌，截至發稿，該股跌超 19%，報 10.16 美元。消息面上，美國食品藥品監督管理局 (FDA) 暫停了該公司計劃進行的流感疫苗臨牀試驗，臨牀暫停是因為單個 CIC 2 期試驗參與者發生了嚴重的運動神經病變事件的自發報告。

智通財經 APP 獲悉，週三，諾瓦瓦克斯醫藥 (NVAX.US) 股價大幅下跌，截至發稿，該股跌超 19%，報 10.16 美元。消息面上，美國食品藥品監督管理局 (FDA) 暫停了該公司計劃進行的流感疫苗臨牀試驗，臨牀暫停是因為單個 CIC 2 期試驗參與者發生了嚴重的運動神經病變事件的自發報告。

Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.